This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
CANVAS 1 and 2 trials: Two Phase III, randomised, double-blind, international, multicentre, comparative efficacy and safety trials comparing Zinforo (600 mg IV q12h ± placebo q12h, adjusted for moderate renal impairment) vs vancomycin + aztreonam (1 g IV q12h)2
Response rate at Day 3
Clinical response rates at Day 3 (CANVAS 1 and 2 trials)†3
Zinforo was well tolerated with a safety profile consistent with the cephalosporin class.2
*The lower limit of the 95% CI was above -10%, which met the predefined criteria for non-inferiority.2
‡There is no experience with Zinforo in the treatment of cSSTI in the following patient groups: The immunocompromised; patients with severe sepsis/septic shock; necrotising fasciitis; perirectal abscess; and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
†Zinforo was associated with a non-statistical significant early clinical response defined by cessation of lesion spread and absence of fever.3
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
Abbreviations
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; CANVAS, Ceftaroline fosamil vs Vancomycin in Skin and skin structure infection; CI, confidence interval; MITT, modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; MRSA, Methicillin-resistant Staphylococcus aureus.
Prescribing Information
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion
References
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021